Literature DB >> 18209044

TGF-beta inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector/memory T cells in the presence of sustained TCR signal transduction.

Lopamudra Das1, Alan D Levine.   

Abstract

TGF-beta signaling is critical for controlling naive T cell homeostasis and differentiation; however, the biological and biochemical changes induced by TGF-beta in effector/memory T cells are poorly defined. We show that although TGF-beta inhibits effector/memory peripheral blood T lymphoblast proliferation and IL-2 production, the intensity and kinetics for TCR-induced global tyrosine phosphorylation are markedly increased compared with that in untreated cells or naive T cells. After TCR ligation, tyrosine phosphorylation of proximal tyrosine kinases and docking proteins like linker for activation of T cells is maintained for >30 min in TGF-beta-primed cells compared with untreated cells where phosphorylation of these targets returned to basal levels by 10 min. Extended phosphorylation of linker for activation of T cells in treated peripheral blood T selectively prolongs ERK 1/2 signaling and phospholipase C-gamma1 activation leading to increased Ca(2+) flux. A kinase/phosphatase imbalance could not account for extended phosphorylation as CD45R, SHP-1, and SHP-2 expression remains unaltered. The contradiction between prolonged signal transduction and inhibition of proliferation is partially explained by the observation that TGF-beta priming results in ERK 1/2-independent p21 induction and decreased cyclin D1 expression leading to accumulation of T cells in G(0)/G(1) phases of the cell cycle and cell cycle arrest. Despite inhibition of T cell function by TGF-beta priming, TCR and cytokine signaling pathways are intact and selectively extended, suggesting that suppression in the effector/memory T cell is mediated by reprogramming signal transduction, rather than its inhibition as in the naive T cell.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209044     DOI: 10.4049/jimmunol.180.3.1490

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

Review 2.  The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors:  Miles Piper; Adam C Mueller; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-05-04       Impact factor: 4.784

3.  IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation.

Authors:  Shankar Revu; Jing Wu; Matthew Henkel; Natalie Rittenhouse; Ashley Menk; Greg M Delgoffe; Amanda C Poholek; Mandy J McGeachy
Journal:  Cell Rep       Date:  2018-03-06       Impact factor: 9.423

4.  Comprehensive Molecular Profiles of Functionally Effective MSC-Derived Extracellular Vesicles in Immunomodulation.

Authors:  Hyemee Kim; Min Joung Lee; Eun-Hye Bae; Jin Suk Ryu; Gagandeep Kaur; Hyeon Ji Kim; Jun Yeob Kim; Heather Barreda; Sung Youn Jung; Jong Min Choi; Taeko Shigemoto-Kuroda; Joo Youn Oh; Ryang Hwa Lee
Journal:  Mol Ther       Date:  2020-04-23       Impact factor: 11.454

5.  Leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction induces a novel genetic signature resulting in T-cells refractory to transforming growth factor-β signaling.

Authors:  Navin K Verma; Eugene Dempsey; Aideen Long; Anthony Davies; Sean P Barry; Padraic G Fallon; Yuri Volkov; Dermot Kelleher
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

6.  Exchange protein directly activated by cAMP modulates regulatory T-cell-mediated immunosuppression.

Authors:  Muayad Almahariq; Fang C Mei; Hui Wang; Anthony T Cao; Suxia Yao; Lynn Soong; Jiaren Sun; Yingzi Cong; Ju Chen; Xiaodong Cheng
Journal:  Biochem J       Date:  2015-01-15       Impact factor: 3.857

7.  Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation.

Authors:  Robert N Mahon; Obondo J Sande; Roxana E Rojas; Alan D Levine; Clifford V Harding; W Henry Boom
Journal:  Cell Immunol       Date:  2012-03-14       Impact factor: 4.868

8.  Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway.

Authors:  Debasmita Mandal; Alan D Levine
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

Review 9.  Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.

Authors:  Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2009-10-30       Impact factor: 16.687

10.  IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells.

Authors:  Wendy A Goodman; Alan D Levine; Jessica V Massari; Hideaki Sugiyama; Thomas S McCormick; Kevin D Cooper
Journal:  J Immunol       Date:  2009-07-31       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.